Therapy Areas: Cardiovascular
ESSA Pharma names new director
21 October 2019 -

ESSA Pharma Inc (TSX-V: EPI,NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, has named Ari Brettman as its director, it was reported on Friday.

Presently, Dr Brettman is a Principal in the Blackstone Life Sciences group, having joined Blackstone as part of its acquisition of Clarus in December of 2018. He joined Clarus in September 2014. He is presently a member of the board of directors of Praxis Precision Medicines and Anthos Therapeutics and Observer on the board of directors of Talaris Therapeutics.

Dr Brettman completed a residency in internal medicine and a fellowship in cardiology at Massachusetts General Hospital and was also a National Institutes of Health-sponsored post-doctoral fellow at the MGH Center for Systems Biology. He received his MD from Duke University and his AB in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation fellow at Stanford University, where he studied angiogenesis.



Related Headlines